FDA approves new Alzheimer's drug to slow disease progression - NBC26
FDA approves Kisunla, a new drug to slow Alzheimer's progression, offering hope to millions. Dr. Ferguson emphasizes its significance in targeting dementia mechanisms. The annual Walk to End Alzheimer’s in Neenah, hosted by NBC 26’s Nina Sparano, aims to combat the disease.
Reference News
FDA approves Kisunla, a new drug to slow Alzheimer's progression, offering hope to millions. Dr. Ferguson emphasizes its significance in targeting dementia mechanisms. The annual Walk to End Alzheimer’s in Neenah, hosted by NBC 26’s Nina Sparano, aims to combat the disease.
The FDA approved Kisunla (donanemab-azbt), an Alzheimer’s drug targeting amyloid plaques in early-stage patients, potentially stabilizing disease progression. Clinical trials showed significant improvement in cognitive and functional assessments, with 47% of patients potentially stopping therapy after one year. Safety concerns include ARIA, a side effect requiring MRI monitoring. Kisunla costs $12,522 for six months, with Medicare and Eli Lilly offering support. The approval marks a shift in Alzheimer’s management, emphasizing early diagnosis and potentially reducing lifelong treatment.